// App-Quantinova.ai

: Incidence, Risk, and Markers of Thrombosis in AML Patients - Single Institution Experience

Researchers

Presenter

  • Sayeef Mirza

Principal Investigators

  • Najla Al Ali

  • Hannah Shin

  • Joseph Luke O'Neill

  • Daniel Schwartz

  • Amra Kuc

  • Sammy Abusrur

  • Jose Jesurajan

  • Jameson Kuang

  • Shreyans Patel

  • Sabrina Khalil

  • Sonya Bhaskar

  • Alexander Beard

  • Toaa Abuelenen

  • Ethan Nowell

  • Kevin Ratnasamy

  • Nathan Visweshwar

  • Rami S. Komrokji

  • Michael Jaglal

Medical Centers

  • Department ofMedicine, University of South Florida, Tampa, FL

  • Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Morsani School of Medicine, Tampa

  • USF Morsani College of Medicine, Seoul, FL.

  • University of South Florida, Department of Family Medicine, Tampa, FL

  • Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

  • Moffitt Cancer Center, Tampa, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • Granulocyte colony-stimulating factor

  • Granulocyte-macrophage-colony stimulating factor

  • TIMP Metallopeptidase Inhibitor 1

  • White Blood Cell

Drug/Treatment

  • GM-CSF

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved